Supercharged immune cells aim to beat back tough leukemia
NCT ID NCT02782546
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether giving patients with hard-to-treat acute myeloid leukemia (AML) a special type of immune cell—called a cytokine-induced memory-like natural killer (NK) cell—after a stem cell transplant can improve their chances of staying cancer-free. About 60 adults with AML that did not respond to standard treatments will receive a donor stem cell transplant followed by these memory-like NK cells. The goal is to see if this combination can boost leukemia-free survival at 100 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- memory-like natural killer (NK) cells
- What this could lead to
- If successful, this could offer a new treatment option for patients with hard-to-treat acute myeloid leukemia, potentially improving their chances of staying cancer-free.
- What could go wrong
- This is an early-phase trial with only 60 participants, so results may not apply to everyone. There are risks of graft failure, severe graft-versus-host disease, or the treatment not working as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?